Skip to main content
Premium Trial:

Request an Annual Quote

Carna Biosciences and CrystalGenomics to Provide Crystallographic Services for Rigel

NEW YORK, June 20 (GenomeWeb News) - Carna Biosciences and CrystalGenomics have signed a joint agreement to provide protein crystallography services for Rigel Pharmaceuticals, the companies said today.


Carna Biosciences, a Japanese biotech that specializes in active kinase protein expression, and CrystalGenomics, a Korean structure-based drug discovery firm, began offering joint crystallographic services in February.


The relationship with Rigel began with the company's purchase of protein kinases from Carna a year ago, Carna Biosciences said.


Financial terms for the agreement were not provided.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.